Antibiotic resistance is a major worldwide problem. With excellent efficacy, bioavailability, and minimal toxicity, the frequently prescribed fluoroquinolones are an extremely important drug class. The long-term goals of the Zechiedrich laboratory are to determine how gram-negative bacteria respond to and develop resistance to antimicrobial agents and to use this knowledge to improve diagnosis of antibiotic-resistant bacterial infections, to prolong the usefulness of current drugs, and to aid in the design of new therapeutic modalities. In previous funding periods, we constructed an evolving HIPAA compliant Oracle database that combines patient, hospital, and microbiological data from gram-negative clinical isolates collected since 1999. We discovered that known fluoroquinolone resistance mechanisms account for the resistance phenotype in approximately half of fluoroquinolone-resistant E. coli clinical isolates; therefore, additional unknown resistance mechanisms must exist. To uncover these mechanisms, we developed a unique approach that incorporates genome pooling, sequencing, and SNP analysis. We uncovered extremely problematic novel clinical isolates (resistant to all but two antibiotics and with very high fluoroquinolone MICs). The genomes of these isolates diverged from and could not be mapped to reference genomes. Conserved among all other fluoroquinolone-resistant pools, we found the well-known SNP in the gyrA target gene and three novel SNPs relative to drug-susceptible reference genomes. We also found 283 SNPs in 173 genes associated with fluoroquinolone resistance and resistance to specific additional antimicrobial agents. Relative to a fluoroquinolone-resistant reference genome, we found 35 novel SNPs associated with a fluoroquinolone-susceptible phenotype.
The aims of this proposal are Aim 1: Predict how Identified Genetic Variants Alter the Encoded Protein Structure and Function, Aim 2: Define Function of Discovered Genetic Variants, Aim 3: Determine the Molecular Mechanisms of Discovered Protein Variants, and Aim 4: Continue to Discover Genetic Variants Associated with Fluoroquinolone Susceptibility or Fluoroquinolone Resistance Phenotypes. Our team, in the Texas Medical Center in Houston, Texas, is composed of a molecular microbiologist (Zechiedrich), a physician scientist (Hamill), a genomics expert (Sucgang), a computational biologist (Barth), and a crystallographer (Lee). The foundational knowledge gained in achieving these goals is required before new drugs or new targets for new drugs can be identified. A better understanding of how resistance arises will provide vital clues to how it may be avoided. Moreover, the identification of SNPs associated with fluoroquinolone resistance or susceptibility will provide physicians tools to prescribe antibiotics that will be effective, thus saving lives, money, and preserving the current arsenal of antibiotics.

Public Health Relevance

People, particularly the very young, the very old, those with or who have survived cancer, and those with HIV are dying from bacterial infections that are resistant to antibiotics. This project aims to uncover how these bacteria resist antibiotics and to identify potential new drug targets. Results from our proposed work will ultimately help save lives, save our country the billions of dollars in healthcare costs when the wrong antibiotic is given, preserve the current arsenal of antibiotics, and prevent antibiotic resistance.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
3R01GM115501-03S1
Application #
9539894
Study Section
Program Officer
Fabian, Miles
Project Start
2015-08-15
Project End
2019-05-31
Budget Start
2017-06-01
Budget End
2018-05-31
Support Year
3
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Conley, Zachary C; Bodine, Truston J; Chou, Andrew et al. (2018) Wicked: The untold story of ciprofloxacin. PLoS Pathog 14:e1006805
Bizard, Anna H; Yang, Xi; Débat, Hélène et al. (2018) TopA, the Sulfolobus solfataricus topoisomerase III, is a decatenase. Nucleic Acids Res 46:861-872
Bodine, Truston J; Evangelista, Michael A; Chang, Huan Ting et al. (2017) Escherichia coli DNA ligase B may mitigate damage from oxidative stress. PLoS One 12:e0180800
Wang, Qian; Irobalieva, Rossitza N; Chiu, Wah et al. (2017) Influence of DNA sequence on the structure of minicircles under torsional stress. Nucleic Acids Res 45:7633-7642
Hardee, Cinnamon L; Arévalo-Soliz, Lirio Milenka; Hornstein, Benjamin D et al. (2017) Advances in Non-Viral DNA Vectors for Gene Therapy. Genes (Basel) 8:
Koire, Amanda; Gilbert, Brian E; Sucgang, Richard et al. (2016) Repurposed Transcriptomic Data Reveal Small Viral RNA Produced by Influenza Virus during Infection in Mice. PLoS One 11:e0165729
Bates, David; Pettitt, B Montgomery; Buck, Gregory R et al. (2016) Importance of disentanglement and entanglement during DNA replication and segregation: Comment on: ""Disentangling DNA molecules"" by Alexander Vologodskii. Phys Life Rev 18:160-164
Sung, Nuri; Lee, Jungsoon; Kim, Ji Hyun et al. (2016) 2.4?Å resolution crystal structure of human TRAP1NM, the Hsp90 paralog in the mitochondrial matrix. Acta Crystallogr D Struct Biol 72:904-11
Hornstein, Benjamin D; Roman, Dany; Arévalo-Soliz, Lirio M et al. (2016) Effects of Circular DNA Length on Transfection Efficiency by Electroporation into HeLa Cells. PLoS One 11:e0167537
Chou, Andrew; Nuila, Ricardo E; Franco, Luis M et al. (2016) Prevalence of hypervirulent Klebsiella pneumoniae-associated genes rmpA and magA in two tertiary hospitals in Houston, TX, USA. J Med Microbiol 65:1047-8

Showing the most recent 10 out of 12 publications